Optiscan Imaging has submitted its FDA dossier for InSpecta®, marking a crucial step toward US veterinary market entry, while progressing clinical studies for InVue® and InForm® ahead of further FDA submissions in 2026.
- FDA dossier submitted for InSpecta® veterinary device
- Clinical studies advancing for InVue® and InForm® devices
- R&D spend of $1.67 million supports regulatory progress
- Commercial launch preparations underway for US veterinary market
- Cash reserves support 6.2 quarters of operations
InSpecta® FDA Dossier Submission Accelerates US Veterinary Market Entry
Optiscan Imaging Ltd (ASX:OIL) has taken a decisive leap towards commercialising its veterinary imaging device, InSpecta®, in the lucrative US market by lodging its FDA regulatory dossier just before the end of March 2026. This submission, achieved less than a year after the device's June 2025 debut, positions Optiscan to tap into the nearly US$12 billion US veterinary sector with a product tailored for microscopic imaging in animal medicine. The regulatory milestone not only advances InSpecta®’s commercial launch preparations but also lays the groundwork for the company’s broader US expansion strategy. This development builds on momentum from the company’s earlier FDA dossier submission for InSpecta® veterinary imaging device, which marked the transition from development to formal regulatory review.
Clinical Studies Progressing for InVue® and InForm® FDA Submissions
While InSpecta® moves through regulatory channels, Optiscan is accelerating clinical studies for its flagship medical devices InVue® (precision surgery) and InForm® (digital pathology), both slated for FDA submissions in the second half of 2026. The company has active trials at multiple sites including the Royal Melbourne Hospital, St John of God Murdoch Hospital, and Australian Clinical Labs, collectively recruiting patients across breast, head and neck, and multiple tissue types. Notably, the breast cancer study at Royal Melbourne has completed 17 of 50 planned cases, with recruitment boosted by new clinical research assistants and a second site at Frances Perry House. The head and neck cancer study at St John of God Murdoch has initiated imaging with six patients enrolled, preparing to expand to InVue® imaging pending ethics approval. Meanwhile, Australian Clinical Labs has amassed 26 datasets across diverse tissues, bolstering Optiscan’s digital pathology image bank. This clinical momentum underpins the company’s regulatory ambitions and reflects learnings from earlier collaborations such as the partnership with Australian Clinical Labs to deploy InForm digital pathology platform and the launch of head and neck cancer imaging study in Perth.
Product Development Advances and Regulatory Readiness
Behind the scenes, Optiscan has made steady progress transitioning its product pipeline from design to real-world testing and compliance. The company completed pre-compliance electrical safety and electromagnetic compatibility testing, essential for FDA acceptance. Documentation for device history and design records was finalised to support manufacturing and regulatory filings. Software updates improved usability based on early clinical feedback, while probe designs were refined for durability and sterilisation validation continued in the US. Additionally, AI development for the next-generation flexible gastrointestinal endomicroscope advanced in partnership with Monash University, aligning outputs with clinical needs. These efforts collectively underpin the regulatory dossier submissions and future manufacturing scalability.
Commercial Launch Preparations and Market Engagement
Optiscan is actively preparing for the commercial launch of InSpecta® in the US veterinary market, refining sales and marketing assets and engaging key veterinary surgeons and oncologists at major conferences such as the Veterinary Meeting & Expo in Florida and the Veterinary Cancer Society conference in Georgia. These interactions validate clinical use cases and support market segmentation strategies. The company is also transitioning to the HubSpot CRM platform to enable more structured and data-driven sales activities ahead of launch. Concurrently, Optiscan is reassessing its commercial resourcing to ensure adequate coverage for the planned 2026 launch. In parallel, the company continues to engage life sciences stakeholders for its ViewnVivo® product across the US, Europe, and China, maintaining a measured approach to market opportunities and commercial strategy refinement.
Financial Position and Staffing Updates
Optiscan reported a net cash outflow from operations of $2.421 million for the quarter, driven primarily by $1.672 million in R&D expenditure focused on clinical and regulatory activities. The company ended the quarter with $15.126 million in cash and cash equivalents, providing an estimated 6.2 quarters of funding at current burn rates. Staffing expanded with new hires in clinical research, IT systems, precision technology, and software engineering to support the increased regulatory and clinical workload. However, a strategic realignment of the US business development team saw the departure of Shayra Leon. Recruitment is underway for four clinical research associates to support upcoming US clinical studies at the Mayo Clinic in Rochester, where preparations for two FDA-supporting trials are advancing.
Bottom Line?
Optiscan’s FDA submission for InSpecta® and ongoing clinical trials set a demanding timetable for 2026, with regulatory approvals and commercial launches poised to define its near-term trajectory.
Questions in the middle?
- Will FDA approvals for InVue® and InForm® follow InSpecta®’s submission timeline?
- How effectively can Optiscan scale commercial operations for the US veterinary market launch?
- What impact will clinical trial outcomes have on regulatory confidence and investor sentiment?